Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an Adjuvanted Plant-Based COVID-19 Vaccine
Read more
-
-
Medicago submits Phase 3 data to Health Canada for its plant-based COVID-19 vaccine candidate
Read more -
Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
Read more -
Medicago to launch clinical trials for COVID-19 vaccine candidate with GSK’s pandemic adjuvant in Japan
Read more -
Medicago and GSK announce positive interim phase 2 results for adjuvanted COVID-19 vaccine candidate
Read more -
Health Canada initiates the review of the rolling submission for the first canadian-based COVID-19 vaccine candidate
Read more -
Medicago and GSK start phase 3 trial of adjuvanted COVID-19 vaccine candidate
Read more -
Medicago and GSK announce start of phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate
Read more -
Medicago announces positive phase 1 results for its COVID-19 vaccine candidate
Read more -
Medicago signs agreements with the government of Canada to supply up to 76 million doses of its recombinant plant-derived COVID-19 vaccine
Read more -
Medicago begins phase 1 clinical trials for its COVID-19 vaccine candidate
Read more -
Dynavax and Medicago announce collaboration to develop a novel adjuvanted COVID-19 vaccine candidate
Read more